NO20014845L - Anvendelse av arylalkanoylpyridaziner - Google Patents

Anvendelse av arylalkanoylpyridaziner

Info

Publication number
NO20014845L
NO20014845L NO20014845A NO20014845A NO20014845L NO 20014845 L NO20014845 L NO 20014845L NO 20014845 A NO20014845 A NO 20014845A NO 20014845 A NO20014845 A NO 20014845A NO 20014845 L NO20014845 L NO 20014845L
Authority
NO
Norway
Prior art keywords
arylalkanoylpyridazines
osteoporosis
atherosclerosis
tumors
aids
Prior art date
Application number
NO20014845A
Other languages
English (en)
Other versions
NO20014845D0 (no
Inventor
Jonas Rochus
Michael Wolf
Norbert Beier
Franz-Werner Kluxen
Claus Fittschen
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20014845D0 publication Critical patent/NO20014845D0/no
Publication of NO20014845L publication Critical patent/NO20014845L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører anvendelse av forbindelser med formel (I) d) NH-CO-B hvor R1, R2, Q og B har betydningene an- gitt i krav l, og/eller deres fysiologisk forenlige salter, til fremstilling av et medikament for behandling av osteoporose, tumorer, aterosklerose, reumatoid artritt, multippel sklerose, diabetes mellitus, ulcerøs kolitt og AIDS.
NO20014845A 1999-04-06 2001-10-05 Anvendelse av arylalkanoylpyridaziner NO20014845L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915364A DE19915364A1 (de) 1999-04-06 1999-04-06 Verwendung von Arylalkanoylpyridazinen
PCT/EP2000/002280 WO2000059484A2 (de) 1999-04-06 2000-03-15 Verwendung von arylalkanoylpyridazinen

Publications (2)

Publication Number Publication Date
NO20014845D0 NO20014845D0 (no) 2001-10-05
NO20014845L true NO20014845L (no) 2001-10-05

Family

ID=7903583

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014845A NO20014845L (no) 1999-04-06 2001-10-05 Anvendelse av arylalkanoylpyridaziner

Country Status (18)

Country Link
EP (1) EP1143944A3 (no)
JP (1) JP2002541095A (no)
KR (1) KR20020000550A (no)
CN (1) CN1355702A (no)
AR (1) AR023261A1 (no)
AU (1) AU3811600A (no)
BR (1) BR0009549A (no)
CA (1) CA2367051A1 (no)
CZ (1) CZ20013598A3 (no)
DE (1) DE19915364A1 (no)
HU (1) HUP0200311A3 (no)
ID (1) ID30381A (no)
MX (1) MXPA01010034A (no)
NO (1) NO20014845L (no)
PL (1) PL350963A1 (no)
RU (1) RU2001129703A (no)
WO (1) WO2000059484A2 (no)
ZA (1) ZA200109120B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481977A4 (en) * 2002-03-01 2006-02-01 Astellas Pharma Inc NITROGENIC HETEROCYCLIC COMPOUND
DE10224888A1 (de) * 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
DE10225574A1 (de) * 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
EP1640010A1 (en) * 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent inducing increase in bone mass
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19915365A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Tetrahydropyridazin-Derivate

Also Published As

Publication number Publication date
AU3811600A (en) 2000-10-23
NO20014845D0 (no) 2001-10-05
AR023261A1 (es) 2002-09-04
HUP0200311A2 (hu) 2002-11-28
JP2002541095A (ja) 2002-12-03
RU2001129703A (ru) 2004-02-20
CZ20013598A3 (cs) 2002-01-16
PL350963A1 (en) 2003-02-24
EP1143944A2 (de) 2001-10-17
BR0009549A (pt) 2002-03-26
ZA200109120B (en) 2003-11-13
MXPA01010034A (es) 2002-04-24
WO2000059484A2 (de) 2000-10-12
ID30381A (id) 2001-11-29
WO2000059484A3 (de) 2001-08-23
CA2367051A1 (en) 2000-10-12
KR20020000550A (ko) 2002-01-05
CN1355702A (zh) 2002-06-26
DE19915364A1 (de) 2000-10-12
EP1143944A3 (de) 2002-09-11
HUP0200311A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
FI971489A0 (fi) Uusia bentsoksatsoleja
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
NO20065178L (no) Tienopyridinderivater
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MXPA06010097A (es) Inhibidores de dipeptidil peptidasa-iv.
WO2004035569A3 (de) Neue verbindungen mit antibakterieller aktivität
GB9903670D0 (en) Liquid crystal compounds
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20060142L (no) Syklisk tertiaer aminforbindelse
DE50209545D1 (de) Flüssigkristallines medium
BR9206823A (pt) Preparação de piperidinas substituídas
CA2037975A1 (en) 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
ATE496056T1 (de) Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
GB0327323D0 (en) Novel pharmaceuticals
DK1831239T3 (da) Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-lambda-lacton og nøgle-mellemprodukter til denne fremgangsmåde
TW200613346A (en) Organoantimony, manufacturing method thereof, active free radical polymerization initiator, polymer manufacture method using the same, and polymer
CA2275253A1 (en) Method for producing n-substituted 3-hydroxypyrazoles
CA2585802A1 (en) Industrial process for the preparation of 17-hydroxy-6.beta.,7.beta.;15.beta.,16.beta.-bismethylene-3-oxo-17.alpha.pregn-4-ene-21-carboxylic acid.gamma.-lactone and key-intermediates for this process
NO20060258L (no) Nematicidale tiazolin-inneholdende fluorobutener
WO2000043375A3 (de) Substituierte arylheterocyclen
DK1250335T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af imidazopyridiner
TW200619250A (en) Resin composition and resin sheet for optical use, and optical semiconductor device
DK1598358T3 (da) Forbindelser indeholdende 3,4-methylendioxythiophen-enheder
NO20013681L (no) Acetyleniske heteroarylsulfonamid- og - fosfinsyreamidhydroksamsyre TACE-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application